◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › V › VRTX

Vertex Pharmaceuticals Inc (VRTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-08-16

Vertex Pharmaceuticals Inc (VRTX) operates in the Biotechnology industry and is headquartered in Boston, United States with about 6,400 employees. Its market capitalization is roughly $129 billion. In the fiscal year ended 2025-12-31, VRTX reported $12.1B in revenue and $4.0B in net income.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Interactive charts & full statements → Open the VRTX valuation workbench →

VRTX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$12.6B	$12.1B	$11.0B	$9.9B	$8.9B	$7.6B	$6.2B	$4.2B	$3.0B	$2.5B	$1.7B	$1.0B	$580M	$1.2B	$1.5B	$1.4B	$143M	$102M	$176M	$199M	$216M
Gross Profit	$10.9B	$10.3B	$9.5B	$8.6B	$7.8B	$6.7B	$5.5B	$3.6B	$2.6B	$2.2B	$1.5B	$907M	$519M	$1.1B	$1.2B	$1.3B	$131M	$88M	$160M	$185M	$204M
Gross Margin %	86.0%	85.0%	86.1%	87.2%	87.9%	88.1%	88.1%	86.8%	86.6%	88.9%	87.6%	87.8%	89.5%	89.2%	81.7%	94.3%	91.1%	86.1%	91.1%	93.0%	94.4%
Operating Income (EBIT)	$4.9B	$4.8B	($233M)	$3.8B	$4.3B	$2.8B	$2.9B	$1.2B	$635M	$123M	$10M	($469M)	($692M)	($903M)	$2M	$114M	($696M)	($613M)	($463M)	($420M)	($229M)
Operating Margin %	38.6%	39.4%	-2.1%	38.8%	48.2%	36.7%	46.0%	28.8%	20.8%	5.0%	0.6%	-45.4%	-119.3%	-74.5%	0.1%	8.1%	-485.5%	-601.1%	-263.6%	-210.9%	-105.9%
Net Income	$4.4B	$4.0B	($536M)	$3.6B	$3.3B	$2.3B	$2.7B	$1.2B	$2.1B	$263M	($112M)	($558M)	($739M)	($445M)	($107M)	$30M	($755M)	($642M)	($460M)	($391M)	($207M)
Net Margin %	34.9%	32.7%	-4.9%	36.7%	37.2%	30.9%	43.7%	28.3%	68.8%	10.6%	-6.6%	-54.1%	-127.2%	-36.7%	-7.0%	2.1%	-526.3%	-628.7%	-262.0%	-196.6%	-95.6%
EBITDA	$5.4B	$4.9B	$486M	$4.6B	$4.4B	$2.9B	$3.3B	$1.6B	$707M	$103M	$75M	($411M)	($599M)	($555M)	$42M	$134M	($705M)	($599M)	($426M)	($385M)	($200M)
Earnings Per Share (EPS)	$17.18	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.30	$4.51	$8.09	$1.04	$-0.46	$-2.31	$-3.14	$-1.98	$-0.50	$0.14	$-3.77	$-3.70	$-3.27	$-3.03	$-1.83
Shares Outstanding (M)	256M	258M	258M	260M	259M	260M	263M	261M	259M	253M	245M	241M	235M	225M	212M	209M	200M	173M	141M	129M	113M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$3.3B	$3.0B	$3.2B	$3.1B	$3.0B	$2.8B	$2.9B	$2.8B
Gross Profit	$2.8B	$2.6B	$2.8B	$2.7B	$2.6B	$2.4B	$2.5B	$2.4B
Gross Margin %	85.3%	86.9%	85.6%	86.5%	86.2%	86.9%	85.5%	85.8%
Operating Income (EBIT)	$1.2B	$1.1B	$1.3B	$1.2B	$1.2B	$630M	$1.0B	$1.1B
Operating Margin %	37.4%	38.1%	40.3%	38.6%	38.8%	22.8%	35.2%	40.3%
Net Income	$1.1B	$1.0B	$1.2B	$1.1B	$1.0B	$646M	$913M	$1.0B
Net Margin %	33.0%	34.5%	36.9%	35.2%	34.8%	23.3%	31.4%	37.7%
EBITDA	$1.4B	$1.3B	$1.4B	$1.4B	$1.3B	$782M	$1.2B	$1.3B
Earnings Per Share (EPS)	$4.30	$4.02	$4.65	$4.20	$3.99	$2.49	$3.50	$4.01
Shares Outstanding (M)	256M	256M	256M	258M	259M	260M	260M	261M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$4.3B	$3.6B	($493M)	$3.5B	$4.1B	$2.6B	$3.3B	$1.6B	$1.3B	$845M	$236M	($365M)	($513M)	($52M)	$268M	$144M	($635M)	($428M)	($226M)	($252M)	($22M)
Capital Expenditures (CapEx)	$497M	$438M	$298M	$258M	$205M	$235M	$260M	$75M	$96M	$259M	$57M	$45M	$51M	$51M	$71M	$95M	$38M	$23M	$32M	$32M	$32M
Free Cash Flow (FCF)	$3.8B	$3.2B	($790M)	$3.3B	$3.9B	$2.4B	$3.0B	$1.5B	$1.2B	$586M	$180M	($411M)	($564M)	($103M)	$197M	$49M	($673M)	($451M)	($259M)	($285M)	($55M)
FCF Margin %	30.1%	26.5%	-7.2%	33.2%	44.0%	31.8%	48.2%	35.9%	38.6%	23.5%	10.5%	-39.8%	-97.2%	-8.5%	12.9%	3.5%	-469.8%	-442.0%	-147.4%	-143.2%	-25.4%
Dividends Paid	—	—	—	—	—	$102M	$265M	$10M	$21M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$291M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$1.1B	$1.4B	$498M	$1.2B	$1.1B	$819M	$585M	$1.4B
Capital Expenditures (CapEx)	$112M	$133M	$149M	$102M	$146M	$41M	$93M	$68M
Free Cash Flow (FCF)	$1.0B	$1.3B	$349M	$1.1B	$927M	$778M	$492M	$1.3B
FCF Margin %	30.4%	43.4%	10.8%	37.0%	31.3%	28.1%	16.9%	47.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$27.4B	$26.1B	$22.5B	$22.7B	$18.2B	$13.4B	$11.8B	$8.3B	$6.2B	$3.5B	$2.9B	$2.5B	$2.3B	$2.3B	$2.8B	$2.2B	$1.7B	$2.0B	$980M	$601M	$922M
Cash & Cash Equivalents	$6.1B	$5.1B	$4.6B	$10.4B	$10.5B	$6.8B	$6.0B	$3.1B	$2.6B	$1.7B	$1.2B	$715M	$625M	$569M	$489M	$475M	$243M	$447M	$389M	$356M	$213M
Total Liabilities	$7.2B	$7.5B	$6.1B	$5.2B	$4.2B	$3.3B	$3.1B	$2.2B	$1.8B	$1.5B	$1.6B	$1.4B	$1.2B	$963M	$1.5B	$1.2B	$1.2B	$859M	$742M	$330M	$416M
Total Debt (Short + Long-Term)	$0M	$83M	$92M	$84M	$89M	$80M	$42M	$39M	$572M	$586M	$806M	$784M	$786M	$458M	$682M	$651M	$537M	$186M	$393M	$20M	$124M
Total Shareholders' Equity	$20.2B	$18.7B	$16.4B	$17.6B	$13.9B	$10.1B	$8.7B	$6.1B	$4.4B	$2.0B	$1.3B	$1.1B	$1.1B	$1.4B	$1.2B	$966M	$504M	$1.1B	$239M	$271M	$506M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRTX viewer.

VRTX Metric Deep Dives

Other Companies in Biotechnology

GILD · Gilead Sciences — $186 billion
ONESOURCE · OneSource Specialty Pharma Limited — ₹183 billion
CONCORDBIO · Concord Biotech Limited — ₹156 billion
4587 · PeptiDream Inc. — JPY 138 billion
4565 · Nxera Pharma Co., Ltd. — JPY 119 billion
6990 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — HK$110 billion
BLUEJET · Blue Jet Healthcare Limited — ₹100 billion
1177 · Sino Biopharmaceutical Limited — HK$97 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← VRTS All “V” companies VRVD →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.